Mindfulness and Repetitive Negative Thinking (RNT): their associations with markers of brain health
Silver Santé Study researchers from University College London (UCL) will present at this year’s prestigious AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders 15th – 20th March 2022 (online/Barcelona).
The conference, which will take place as a hybrid event with sessions being held virtually and in-person in Barcelona, attracts international medical and scientific professionals worldwide. Held annually, the AD/PD™ conference combines distinct neurodegenerative diseases in one setting, examining their similarities and differences and focusing on the latest advances in science and therapy that will lead to methods of prevention, treatment, and improvements in the diagnosis of Alzheimer’s and Parkinson’s Diseases and related neurological disorders.
PhD candidate, Tim Whitfield, will present findings on the effect of a mindfulness-based versus health self-management intervention on cognitive performance in older adults with Subjective Cognitive Decline (SCD), based on the Silver Santé SCD-Well randomized control trial. The trial recruited 147 older adults with SCD from memory clinics in four European countries to take part in an 8-week mindfulness or health self-management intervention, with a 6-month follow-up.
Harriet Demnitz-King, also a PhD candidate at UCL, will discuss research on the association between Repetitive Negative Thinking (RNT) and blood-based biomarkers of stress, inflammation, and neurodegeneration. Findings suggest that RNT is positively associated with a marker of neurodegeneration but not with markers of stress or inflammation.
Former MSc student at UCL, Rachel Morse, will present findings on the association of RNT with cognitive and physical health in older adults at risk of dementia. Research undertaken as part of the project suggests that RNT was associated with worse self-reported physical and cognitive health in older adults.
Dr Natalie Marchant, who led the SCD-Well trial and supervised the research projects that will be presented at the conference, says: “The AD/PD™ 2022 International Conference provides an invaluable opportunity for us to share our Silver Santé Study findings with international researchers, scientists and clinicians. We look forward to hearing from other scientists about their own most recent findings in this important field of research.”
For further information and to register for the AD/PD™ conference visit https://adpd.kenes.com/